Methods of treating pancreatic cancer
Described herein are methods and compositions for the treatment of pancreatic cancer in a subject in need thereof. The pancreatic cancer may be resistant to other therapeutic regimens. The methods may comprise administering ARDA compounds to the subject.
1. A method of treating pancreatic cancer comprising
administering to a patient with pancreatic cancer a therapeutically effective amount of an ARDA compound or a pharmaceutically acceptable salt thereof,
wherein the ARDA compound is of formula (I)
or a pharmaceutically acceptable salt thereof,
wherein
L is a covalent bond or a bivalent, straight or branched, optionally substituted C 1 -C 4 alkylene; and
A is —OH, —OC(O)CH 3 , imidazolyl or pyridyl, wherein the imidazolyl or pyridyl is optionally substituted with —C 1 -C 4 alkyl, —OC 1 -C 4 alkyl and/or -halogen.
2. The method of claim 1 , wherein the ARDA compound is galeterone of formula:
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the ARDA compound is an acetate prodrug of galeterone of formula:
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the ARDA compound is of formula
or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the patient is resistant to other therapies.
6. The method of claim 5 , wherein the other therapies comprise surgery, radiation therapy, chemotherapy or combinations thereof.
7. The method of claim 1 , wherein the patient is resistant to other therapeutic agents.
8. The method of claim 1 , wherein the patient has undergone surgery.
9. The method of claim 1 , wherein the patient has undergone radiation therapy.
10. The method of claim 1 , wherein the patient has undergone treatment with chemotherapy.
11. The method of claim 1 , wherein the pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC).
12. The method of claim 11 , wherein the pancreatic ductal adenocarcinoma is gemcitabine resistant.
13. The method of claim 11 , wherein the pancreatic ductal adenocarcinoma is gemcitabine naive.
14. The method of claim 11 , wherein the pancreatic ductal adenocarcinoma is gemcitabine/erlotinib resistant.
15. The method of claim 1 , wherein in the pancreatic cancer is androgen dependent.
16. The method of claim 1 , wherein the ARDA compound is administered concurrently with other therapeutic agents.
17. The method of claim 1 , wherein the ARDA compound is administered sequentially with other therapeutic agents.
18. The method of claim 16 , wherein the other therapeutic agents comprise chemotherapy.
19. The method of claim 18 , wherein the chemotherapy comprises gemcitabine.
20. The method of claim 1 , wherein the ARDA compound is administered at different time intervals and concurrently with gemcitabine.